Medical Information Only. Consult your healthcare provider before enrolling in any clinical trial.
Vermont: below-average open trial sites
60 of 191 in-state trials are recruiting (31%); below the 37% national average by 6 percentage points, with Phase 2 weight.
According to ClinicalTrials.gov-derived indexes, Vermont sits in the lower half of US states by in-state trial count (#50 of 52 states by registered in-state trial count).
Vermont: 191 US clinical trials with in-state sites, 60 recruiting.
Vermont has 191 registered US clinical trials with a study site in-state, 60 of them currently recruiting (below the 37% national average by 6 percentage points). 24 of these trials are in Phase 3 (late-stage) and 51 in Phase 2. The most frequently studied condition in Vermont is Opioid-Related Disorders, with 7 linked trials.
Thin-volume Vermont archive
Vermont indexes 191 in-state trials (p4 by registry volume among 52 states with sites). Treat this page as a compact local index (thin-volume · mid-open), then jump to recruiting trials or methodology rather than expecting hub-scale coverage.
Below-average open, early-phase tilt
Vermont still shows 60 recruiting of 191 in-state trials (31% open), but below the 37% national average by 6 percentage points, so archived statuses weigh heavier than the national baseline.
- 31%
- open (below national share)
- 60
- still recruiting despite cool share
- 51
- Phase 2 rows in this footprint
- 7
- top: Opioid-Related Disorders
Recruiting share is below the 37% national average by 6 percentage points. Counts include every study with at least one recorded site in the state. Registry reference only, not medical advice.
Vermont vs all states by indexed in-state trial count
Where this state's ClinicalTrials.gov site count sits among every state with at least one listed trial (coverage density, not care quality)
191 Top 96% more indexed trials than 4% of 52 states
States, banded by indexed in-state trial count
Each bar is a band; taller bars hold more states. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov · 2026-08-08
Key findings
What ClinicalTrials.gov does not surface for Vermont on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Vermont open-enrollment share sits below the national baseline.
60 of 191 in-state trials (31.4%) are recruiting, against 37% nationally (-5.6 percentage points). Counts include every study with at least one recorded site in the state.
-
Burlington dominates Vermont's trial geography.
Burlington lists 149 of 191 in-state trials (78%) across 50 named facilities. Cities need five or more listed trials to appear here; locations are as filed by sponsors.
-
Opioid-Related Disorders is the most-studied condition in Vermont.
7 of 191 in-state trials (3.7%) list Opioid-Related Disorders. That is a local concentration figure, not a national disease ranking.
-
One sponsor accounts for a large share of Vermont trials.
University of Vermont appears on 49 of 191 in-state trials (25.7%). Sponsor identity is as filed on ClinicalTrials.gov.
-
Most Vermont indexed trials have already finished enrollment.
107 of 191 (56%) are completed. The open share above is the remainder that still lists recruiting.
By Status
| Status | Trial count |
|---|---|
| Completed | 107 |
| Recruiting | 60 |
| Active | 24 |
By Phase
| Phase | Trial count |
|---|---|
| NA | 60 |
| Phase 2 | 51 |
| Phase 1 | 27 |
| Phase 3 | 24 |
| Phase 4 | 6 |
Top Conditions
Top Sponsors
Where trials run in Vermont
Burlington carries 149 of Vermont's 191 indexed trials (78%) across 50 named sites, ahead of White River Junction at 14. 5 cities clear five listed trials, together naming 72 distinct sites.
| City | Trials | Listed sites |
|---|---|---|
| Burlington | 149 | 50 |
| White River Junction | 14 | 6 |
| Colchester | 10 | 5 |
| Bennington | 8 | 7 |
| South Burlington | 5 | 4 |
Distinct trials and named sites per city, as filed with ClinicalTrials.gov; cities under five trials omitted. Vintage 2026-08-08.
Volume low
Vermont indexes 191 in-state trials (p4 by registry volume among 52 states with sites).
Vermont: in-state trial volume sits in the thin tercile
Geography is concentrated: Burlington alone accounts for 78% of Vermont's indexed trials (149 of 191), with White River Junction a distant second at 14.
Phase mix: 24 Phase 3 vs 51 Phase 2 (early-phase heavy).
Top condition: Opioid-Related Disorders (7 trials); top sponsor University of Vermont (49).
thin-volume · mid-open figures (191 trials · 31% open) describe registry geography under the volume low read, not clinic capacity or protocol fit. Confirm status on ClinicalTrials.gov before acting.
States near Vermont on in-state trial volume
Cross-state peers under the volume low read (thin-volume · mid-open), not the same-state browse list.
Similar thin-volume peers (± open share)
- North Dakota · 235 trials · 19% recruiting
- Montana · 250 trials · 22% recruiting
- West Virginia · 277 trials · 36% recruiting
- Maine · 315 trials · 23% recruiting
- Wyoming · 17 trials · 35% recruiting
Similar mid-open peers (± trial volume)
- District of Columbia · 31% recruiting · 2,316 trials
- Colorado · 31% recruiting · 5,273 trials
- South Dakota · 31% recruiting · 273 trials
- Georgia · 32% recruiting · 5,195 trials
- Kentucky · 32% recruiting · 2,183 trials